A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth
Seiji Kawa1, Hirohisa Matsushita, Hirokazu Ohbayashi
1Division of Oncology, Institute of Medical Science, University of Tokyo, Shirokanedai 4-6-1, Minato-ku, Tokyo 108-8639, Japan.
Abstract:
Overexpression of ErbB2 in breast cancer is associated with increased recurrence and worse prognosis. Accumulating evidences suggest that molecular targeted therapy is a promising anticancer strategy. In this study, we produced a novel anti-ErbB2 monoclonal antibody, 6G10, that recognized an epitope distinct from the trastuzumab binding site. 6G10 induced aggregation of BT474 breast cancer cells and inhibited proliferation of various breast cancer cell lines including BT474. A growth inhibition assay showed that 6G10 had EC(50) values comparable to trastuzumab, indicating that the drugs have a similar level of potency. Furthermore, intraperitoneal administration of 6G10 completely inhibited the growth of xenografted tumors derived from BT474 and SK-BR-3 cells. These data suggested that 6G10 has great therapeutic potential and could be administered to patients alternatively, or synergistically, with trastuzumab.
Insights
A new antibody, 6G10, effectively targets ErbB2-positive breast cancer cells, inhibiting tumor growth in preclinical models. This novel antibody shows therapeutic potential as an alternative or supplement to existing treatments like trastuzumab.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- ErbB2 overexpression in breast cancer correlates with poor prognosis and recurrence.
- Molecular targeted therapies offer a promising strategy for cancer treatment.
- Trastuzumab is a standard therapy targeting ErbB2, but resistance and alternative targets are areas of active research.
Purpose of the Study:
- To develop and characterize a novel anti-ErbB2 monoclonal antibody, designated 6G10.
- To evaluate the efficacy of 6G10 in inhibiting breast cancer cell proliferation and tumor growth.
- To assess the therapeutic potential of 6G10 as a standalone or combination therapy.
Main Methods:
- Production and characterization of the anti-ErbB2 monoclonal antibody 6G10.
- In vitro assessment of 6G10's effect on breast cancer cell aggregation and proliferation using assays.
- In vivo evaluation of 6G10's anti-tumor activity in xenograft models.
Main Results:
- 6G10 binds to a distinct epitope compared to trastuzumab.
- 6G10 induced cell aggregation and inhibited proliferation of ErbB2-positive breast cancer cell lines.
- Growth inhibition assays demonstrated 6G10 potency comparable to trastuzumab.
- Intraperitoneal administration of 6G10 completely suppressed tumor growth in xenograft models.
Conclusions:
- The novel anti-ErbB2 antibody 6G10 exhibits significant anti-tumor activity both in vitro and in vivo.
- 6G10 targets a unique epitope, offering a potential alternative or synergistic therapeutic option alongside trastuzumab.
- These findings support the further clinical investigation of 6G10 for ErbB2-positive breast cancer treatment.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...